La vendita allo scoperto per PepGen dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di PepGen. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

PepGen (NASDAQ:PEPG) Azioni, Report sulle vendite allo scoperto

PepGen

PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle and the central nervous system. Its pipeline products are; PGN-EDO51, PGN-EDODM1, and others including PGN-EDO53 and PGN-EDO45.

PepGen Inc

<p>Duke Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DUK#NYSE">DUK</a>) affirms FY2024 Adj EPS guidance from $5.85-6.10 to $5.85-6.10 vs $5.98 analyst estimate..</p>


News

Guidance

Duke Energy Affirms FY24 Adj EPS Guidance Of $5.85-$6.10 vs $5.98 Est

<p>Repare Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPTX#NASDAQ">RPTX</a>) reported quarterly losses of $(0.81) per share which beat the analyst consensus estimate of $(0.83) by 2.41 percent.</p>


Earnings

RPTX

Repare Therapeutics Q3 2024 GAAP EPS $(0.81) Beats $(0.83) Estimate, Cash, Cash Equivalents And Marketable Securities Were $179.4M, Expected To Fund Its Current Operational Plans Into The Second Half Of 2026

<p><strong>Fourth-Quarter and Full-Year 2024 Financial Outlook</strong></p>
<p>Guidance metrics are based on continuing operations.</p>
<p>The Company is providing guidance on tax expense due to the expected fluctuation of its quarterly tax rate, stemming from the deferred tax reserve matter previously disclosed in fourth-quarter 2022. Importantly, the reserve does not impact cash taxes. Some portion of the reserve may reverse in future periods.</p>
<p>The Company closed the sale of its U.S. Sheer Hosiery business on September 29, 2023. For the full year 2023, its U.S. Sheer Hosiery business generated $50 million of net sales and an operating loss of $(2) million.</p>
<p>For fiscal year 2024, which ends on December 28, 2024, the Company currently expects:</p>
<ul>
<li>Net sales from continuing operations of approximately $3.61 billion, which includes projected headwinds of approximately $50 million from last year's U.S. Sheer Hosiery divestiture and approximately $42 million from changes in foreign currency exchange rates. This represents an approximate 4% decrease as compared to prior year on a reported basis and an approximate 2% decrease on an organic constant currency basis.</li>
<li>GAAP operating profit from continuing operations of approximately $174 million.</li>
<li>Adjusted operating profit from continuing operations of approximately $417 million, which includes a projected headwind of approximately $8 million from changes in foreign currency exchange rates.</li>
<li>Pretax charges for restructuring and other action-related charges of approximately $243 million.</li>
<li>GAAP and Adjusted Interest expense of approximately $195 million, which reflects the pay down of debt from the use of net proceeds from the <i>Champion</i> sale and internal cash generation.</li>
<li>GAAP Other expenses of approximately $53 million, which includes approximately $10 million of accelerated amortization of debt issuance costs. Adjusted Other expenses of approximately $43 million.</li>
<li>GAAP and Adjusted Tax expense of approximately $40 million, which includes a net tax benefit primarily related to a release of certain tax reserves.</li>
<li>GAAP loss per share from continuing operations of approximately $(0.32).</li>
<li>Adjusted earnings per share from continuing operations of approximately $0.39.</li>
<li>Cash flow from operations of approximately $250 million.</li>
<li>Capital investments of approximately $50 million, consisting of approximately $40 million of capital expenditures and approximately $10 million of cloud computing arrangements. Per GAAP, capital expenditures are reflected in cash from investing activities and certain cloud computing arrangements are reflected in Other Assets within cash flow from operating activities. The approximate $10 million of cloud computing arrangements is factored into the full year cash flow from operations guidance of approximately $250 million.</li>
<li>Free cash flow of approximately $210 million.</li>
<li>Fully diluted shares outstanding of approximately 355 million.</li>
</ul>
<p>For fourth-quarter 2024, which ends on December 28, 2024, the Company currently expects:</p>
<ul>
<li>Net sales from continuing operations of approximately $900 million, which includes projected headwind of approximately $4 million from changes in foreign currency exchange rates. This represents an approximate 2% increase as compared to prior year on a reported basis and an approximate 3% increase on an organic constant currency basis.</li>
<li>GAAP operating profit from continuing operations of approximately $95 million.</li>
<li>Adjusted operating profit from continuing operations of approximately $115 million, which includes a projected headwind of approximately $1 million from changes in foreign currency exchange rates.</li>
<li>Pretax charges for restructuring and other action-related charges of approximately $20 million.</li>
<li>GAAP and Adjusted Interest expense of approximately $45 million, which reflects the pay down of debt from the use of net proceeds from the <i>Champion</i> sale and internal cash generation.</li>
<li>GAAP Other expenses of approximately $24 million, which includes approximately $10 million of accelerated amortization of debt issuance costs. Adjusted Other expenses of approximately $14 million.</li>
<li>GAAP and Adjusted Tax expense of approximately $5 million, which includes a net tax benefit primarily related to a release of certain tax reserves.</li>
<li>GAAP earnings per share from continuing operations of approximately $0.06.</li>
<li>Adjusted earnings per share from continuing operations of approximately $0.14.</li>
<li>Fully diluted shares outstanding of approximately 357 million.</li>
</ul>
<p>HanesBrands has updated its quarterly frequently-asked-questions document, which is available at <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.Hanes.com%2FFAQ&amp;esheet=54148472&amp;newsitemid=20241107569107&amp;lan=en-US&amp;anchor=www.Hanes.com%2FFAQ&amp;index=1&amp;md5=b4b20882990d535ada47fa19da8098bf">www.Hanes.com/FAQ</a>.</p>


Hanesbrands Sees Q4 Adj. EPS $0.14 Vs $0.12 Est.; Net Sales Of ~$900M Vs $942.13M Est.; FY24 Adj. EPS $0.39 Vs $0.34	 Est.; Net Sales Of ~$3.61B Vs $3.6B Est.

WIIM

Dynatrace shares are trading lower. The company reported Q2 financial results.

<p>XOMA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XOMA#NASDAQ">XOMA</a>) reported quarterly losses of $(1.59) per share which missed the analyst consensus estimate of $(0.44) by 261.36 percent.  The company reported quarterly sales of $9.197 million which beat the analyst consensus estimate of $6.493 million by 41.65 percent.  This is a 1.01K percent increase over sales of $830.000 thousand the same period last year.</p>


Earnings Beats

Earnings Misses

XOMA

XOMA Q3 2024 GAAP EPS $(1.59) Misses $(0.44) Estimate, Sales $9.197M Beat $6.493M Estimate

<p>Trevena (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRVN#NASDAQ">TRVN</a>) reported quarterly losses of $(5.79) per share which beat the analyst consensus estimate of $(7.38) by 21.54 percent.  The company reported $283.00 in sales this quarter. This is a 99.84 percent decrease over sales of $180.00 thousand the same period last year.</p>


TRVN

Trevena Q3 2024 GAAP EPS $(5.79) Beats $(7.38) Estimate, Sales $283.00 Down From $180.00K YoY

<p>The transaction is part of the objective UScellular announced on May 28, 2024, to opportunistically monetize the spectrum that was not included in the proposed sale to T-Mobile; and follows the transactions previously announced on October 18, 2024, to sell a portion of the retained spectrum licenses to Verizon and two other mobile network operators.</p>
<p>Following this transaction, as well as those previously announced, UScellular will have reached definitive agreements to monetize approximately 55%, measured on a MHz-Pops basis, of the spectrum holdings (excluding mmWave) that were excluded from the proposed sale to T-Mobile, for a total consideration of approximately $2.02 billion. &nbsp;</p>


Asset Sales

United States Cellular Enters Agreement With AT&T To Sell Portion Of Its Retained Spectrum Licenses For Total Consideration Of $1.018B

CORRECTION: BCE Q3 2024 Adj. EPS CAD0.75 Misses CAD0.77 Estimate, Sales CAD5.971B Miss CAD6.032B Estimate

<p>UBS  analyst Steven Fisher   initiates coverage on Martin Marietta Materials (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MLM#NYSE">MLM</a>) with a Buy rating and announces Price Target of $730.</p>


Price Target

Initiation

Analyst Ratings

UBS Initiates Coverage On Martin Marietta Materials with Buy Rating, Announces Price Target of $730

Management

EHAB

Enhabit Home Health & Hospice Appoints Ryan Solomon As CFO, Effective Dec. 9

<p>Needham  analyst Bernie McTernan   reiterates Zillow Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/Z#NASDAQ">Z</a>) with a Hold.</p>


Reiteration

Needham Reiterates Hold on Zillow Gr

Dividends

Fidelity National Financial Increases Dividend From $0.48 To $0.50/Share

F&G Annuities & Life Increases Quarterly Dividend From $0.21 To $0.22/Share

<p><strong>Fiscal 2024 Outlook</strong></p>
<p>Thilo Wrede, Vital Farms' Chief Financial Officer, commented: "With another solid performance in the third quarter, I am pleased to again update our guidance for 2024. Our new outlook reflects the strong performance of the business for the first nine months of this year and our good visibility for the fourth quarter of 2024. Our revised guidance is built around a favorable commodity outlook and strong consumer demand supported by our marketing reinvestment strategy. Vital Farms' long-term strategy is built to increase brand awareness, drive deeper loyalty with consumers, and grow our household penetration through focused energies on brand marketing and continuous retail expansion."</p>
<p>For the fiscal year 2024, management now expects:</p>
<ul>
<li>Net revenue of at least $600 million, which represents at least 27% growth versus fiscal year 2023, compared to our previous expectation of at least $590 million, or 25% growth.</li>
<li>Adjusted EBITDA of at least $80 million, which represents at least 65% growth versus fiscal year 2023, compared to our previous expectation of at least $75 million, or 55% growth.</li>
<li>Capital expenditures for the full year in the range of $30 million to $40 million, which is reduced from our previous range of $35 million to $45 million due to updated timing on some key projects. We continue to evaluate our capital allocation priorities, and we will provide updates as necessary in future earnings reports.<br /><br />&nbsp;</li>
</ul>
<p>Vital Farms' guidance includes the effect of lapping an extra shipping week in Q4 2023 and assumes that there are no significant disruptions to the supply chain or its customers or consumers, including any issues from adverse macroeconomic factors. Vital Farms cannot provide a reconciliation between its forecasted Adjusted EBITDA and net income and Adjusted EBITDA Margin and net income margin, their most directly comparable GAAP measures, without unreasonable effort due to the unavailability of reliable estimates for income taxes, among other items. These items are not within our control and may vary greatly between periods and could significantly impact future financial results.</p>


VITL

Vital Farms Sees FY24 Revenue Of At least $600M Vs $598.35M Est.

<p><strong>Z: 15% &#x7C; </strong><a href="https://www.benzinga.com//node/41803768">Zillow Group shares are trading higher after the company reported better-than-expected Q3 financial results.</a></p>
<p>&nbsp;</p>
<p><strong>APP: 32% &#x7C; </strong><a href="https://www.benzinga.com//node/41803196">Applovin shares are trading higher after the company reported better-than-expected Q3 financial results.</a></p>
<p>&nbsp;</p>
<p><strong>CYN: 63% &#x7C; </strong><a href="https://www.benzinga.com//node/41803438">Cyngn Announced Progress Of Its Proprietary Computer Vision Technology For Industrial Autonomous Machines, Built On Nvidia Accelerated Computing</a></p>


Movers

Trading Ideas

Market-Moving News for November 7th

<p>HC Wainwright &amp; Co.  analyst Andrew Fein   reiterates Alector (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALEC#NASDAQ">ALEC</a>) with a Buy and maintains $35 price target.</p>


ALEC

HC Wainwright & Co. Reiterates Buy on Alector, Maintains $35 Price Target

<p><strong>Clear Channel Outdoor</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCO#NYSE">CCO</a>) announced its Q3 earnings on Thursday, October 31, 2024 at 06:00 AM.</p>
<p>Here's a breakdown of the earnings report.</p>
<h3>Earnings</h3>
<p>Clear Channel Outdoor missed estimated earnings by 0.0%, reporting an EPS of $-0.06 versus an estimate of $-0.06.</p>
<p>Revenue was up $32.20 million from the same period last year.</p>
<h3>Overview of Past Earnings</h3>
<p>During the previous quarter, the company beat on EPS by $0.01, leading to a 3.0% drop share price change the next day.</p>
<p>Here's a look at Clear Channel Outdoor's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
<th><strong>Q3 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-0.06</td>
<td>-0.05</td>
<td>-0.17</td>
<td>0.04</td>
<td>-0.08</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-0.06</td>
<td>-0.04</td>
<td>-0.17</td>
<td>0.05</td>
<td>-0.11</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>557.41M</td>
<td>562.37M</td>
<td>478.55M</td>
<td>610.14M</td>
<td>594.92M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>558.99M</td>
<td>558.54M</td>
<td>481.75M</td>
<td>632.11M</td>
<td>526.79M</td>
</tr>
</tbody>
</table>
</p>
<h3>Competitors that recently released earnings</h3>
<p>When analyzing Clear Channel Outdoor's numbers, it's imperative to put them into context by comparing them to those of its competitors, like PubMatic, TechTarget, and National CineMedia.</p>
<ul>
<li>PubMatic announced strong earnings on August 08, 2024, surpassing market expectations. Despite an estimated EPS of $-0.02, PubMatic's actual EPS was $0.17, reflecting a 950.0% increase.</li>
<li>TechTarget's earnings announcement on August 08, 2024 exceeded expectations, with an actual EPS of $0.42 compared to the market's projected EPS of $0.4, resulting in a 5.0% increase.</li>
<li>National CineMedia reported earnings on November 05, 2024 that fell short of expectations, with an actual EPS of $-0.04 compared to the market's estimate of $-0.03, resulting in a -33.33% decrease.</li>
</ul>
<h3>Insights into Competitors' Quarterly Earnings and Stock Performance</h3>
<p>In this detailed analysis, insights are provided into the market's response to the latest earnings releases of key competitors. It highlights the expected and announced earnings per share (EPS) for each company, along with their corresponding stock prices at the close of the announcement day and the open of the following trading day.</p>
<p>
<table>
<thead>
<tr>
<th><strong>Company Name</strong></th>
<th><strong>Date</strong></th>
<th style="text-align: right;"><strong>EPS Expected</strong></th>
<th style="text-align: right;"><strong>EPS Announced</strong></th>
<th><strong>EPS Change Percent</strong></th>
<th><strong>Stock Price At Close</strong></th>
<th><strong>Stock Price at Next Day Open</strong></th>
<th><strong>Price Change Percent</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Clear Channel Outdoor</td>
<td>October 31, 2024</td>
<td style="text-align: right;">-0.06</td>
<td style="text-align: right;">-0.06</td>
<td>0.0%</td>
<td>$1.47</td>
<td>$1.48</td>
<td>0.68%</td>
</tr>
<tr>
<td>PubMatic</td>
<td>August 08, 2024</td>
<td style="text-align: right;">-0.02</td>
<td style="text-align: right;">0.17</td>
<td>950.0%</td>
<td>$19.6</td>
<td>$13.82</td>
<td>-29.49%</td>
</tr>
<tr>
<td>TechTarget</td>
<td>August 08, 2024</td>
<td style="text-align: right;">0.40</td>
<td style="text-align: right;">0.42</td>
<td>5.0%</td>
<td>$29.02</td>
<td>$28.38</td>
<td>-2.21%</td>
</tr>
<tr>
<td>National CineMedia</td>
<td>November 05, 2024</td>
<td style="text-align: right;">-0.03</td>
<td style="text-align: right;">-0.04</td>
<td>-33.33%</td>
<td>$7.3</td>
<td>$7.35</td>
<td>0.68%</td>
</tr>
</tbody>
</table>
</p>
<h3>Comparative Assessment: Estimated in Comparison with Actual Peer Revenues</h3>
<p>The following table compares estimated and announced revenue figures for Clear Channel Outdoor's peers. This comparison provides insights into the revenue performance of these companies, offering valuable context to understand their financial standing within the industry.</p>
<p>
<table>
<thead>
<tr>
<th><strong>Company Name</strong></th>
<th><strong>Estimated Revenue</strong></th>
<th><strong>Announced Revenue</strong></th>
<th><strong>Revenue Surprise Percentage</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Clear Channel Outdoor</td>
<td>557.41M</td>
<td>558.99M</td>
<td>0.28%</td>
</tr>
<tr>
<td>PubMatic</td>
<td>70.12M</td>
<td>67.27M</td>
<td>-4.07%</td>
</tr>
<tr>
<td>TechTarget</td>
<td>58.08M</td>
<td>58.91M</td>
<td>1.44%</td>
</tr>
<tr>
<td>National CineMedia</td>
<td>58.02M</td>
<td>62.40M</td>
<td>7.55%</td>
</tr>
</tbody>
</table>
</p>
<p>To track all earnings releases for Clear Channel Outdoor <a href="https://www.benzinga.com/quote/CCO/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Clear Channel Outdoor: Q3 Earnings Insights

<p>Amylyx Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMLX#NASDAQ">AMLX</a>) reported quarterly losses of $(0.53) per share which beat the analyst consensus estimate of $(0.71) by 25.35 percent.  The company reported $416.000 thousand in sales this quarter. This is a 99.59 percent decrease over sales of $102.693 million the same period last year.</p>


Amplify YieldShares Oil Hedged MLP Income ETF

AMLX

Amylyx Pharma Q3 2024 Adj. EPS $(0.53) Beats $(0.71) Estimate, Sales $416.000K Down From $102.693M YoY

<p>Jefferies  analyst Julien Dumoulin-Smith   initiates coverage on Edison Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EIX#NYSE">EIX</a>) with a Buy rating and announces Price Target of $93.</p>


Jefferies Initiates Coverage On Edison Intl with Buy Rating, Announces Price Target of $93

CING

Cingulate Q3 Net Loss $3.2M

PepGen: EDOs Could Enhance Dystrophin Expression Beyond Scope Of Current Treatments

Leerink Partners analyst Joseph Schwartz has reiterated their bullish stance on PEPG stock, giving a Buy rating yesterday. Joseph Schwartz has give...

Optimistic Outlook on PepGen's DMD Therapy Despite Initial Data: Analyst Reiterates Buy Rating

REGENXBIO releases new data on DMD drug ahead of earnings

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p><strong>PepGen</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/pepg-stock-quote/"><strong>PEPG</strong></a></span>) just reported results for the second quarter of 2024.</p><ul><li>PepGen reported earnings per share of -87 cents. This was below the analyst estimate for EPS of -72 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div><p>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><p>The post <a href="https://investorplace.com/earning-results/2024/08/pepg-stock-earnings-pepgen-for-q2-of-2024/">PEPG Stock Earnings: PepGen Misses EPS for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

PEPG Stock Earnings: PepGen Misses EPS for Q2 2024

PepGen GAAP EPS of -$0.87

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Kura Oncology (KURA – Research Report), Tenaya Thera...

Analysts Offer Insights on Healthcare Companies: Kura Oncology (KURA), Tenaya Therapeutics (TNYA) and PepGen Inc. (PEPG)

Dyne stock tumbles 31% amid drug updates, management changes

Tracking Ole Andreas Halvorsen's Viking Global Portfolio - Q2 2024 Update

PepGen Inc. ( ($PEPG) ) has shared an announcement. Christopher Ashton, Ph.D., has announced his intention to retire from the Board of Directors of...

PepGen Inc. Board Reshuffles as Ashton Plans Retirement

Avidity gets FDA partial clinical hold lifted on DM1 drug candidate

AAPL

ACHC

ADBE

ADPT

AMZN

AVGO

BBIO

BMRN

CAPR

CPRX

DASH

DDOG

DLTR

EWTX

FDMT

FERG

INBX

KURA

LBPH

MSCLF

MSFT

NAMS

NFLX

ORIC

PEPG

PHVS

RGNX

RHHBY

ROIV

RPRX

SLDB

SRPT

TMUS

TNYA

TRDA

TRVI

TTWO

VKTX

VRTX

WDAY

Press Releases

PepGen Inc. (PEPG) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

Legal

PepGen Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights

PepGen Appoints Paul Streck, M.D., MBA, as Executive Vice President, Head of Research & Development

PepGen Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Executive Vice President, Research & Development

PepGen Announces Christopher Ashton, PhD, to Retire from its Board of Directors

PepGen Announces Presentations at the 29th Annual Congress of the World Muscle Society

PepGen to Participate in Upcoming Investor Conferences

Adaptimmune Therapeutics plc - American Depositary Shares

Adaptimmune Therapeutics

Amarin Corporation plc - American Depositary Shares, each representing one Ordinary Share

Comments

PepGen

Vendite allo scoperto

PepGen (NASDAQ:PEPG) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO